PROGRAM CHAIR
Kelly G. Knupp, MD, MSCS, FAES (CHAIR)
Professor of Pediatrics and Neurology
University of Colorado, Anschutz Medical Campus
Aurora, CO
PROGRAM OVERVIEW
This educational activity is designed to help learners better utilize genetic evaluation for patients with developmental and epileptic encephalopathies (DEEs); understand specific therapies indicated for management of DEEs based on clinical efficacy and safety; and review best practices for managing the comprehensive burdens of DEEs with optimized transitions of care and the multidisciplinary health care team.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community-based epileptologists, neurologists, and multidisciplinary HCPs including physician assistants, nurse practitioners, LTC nurses, and primary care nurses participating in multi-disciplinary care of patients with epilepsy.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Recognize the need for genetic evaluation of patients with developmental and epileptic encephalopathies (DEEs) as part of diagnostic work-up
- Support the use of specific therapies indicated for management of DEEs based on clinical efficacy and safety, practical use characteristics, and effects on non-seizure outcomes
- Describe best practices for managing the comprehensive burdens of DEEs through optimized transitions of care as enabled by teams of multidisciplinary health care professionals
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty | Relationship | Manufacturer |
| Kelly G. Knupp, MD | Consultant | Stoke Therapeutics, Encoded Therapeutics, Biocodex, Longboard Pharmaceuticals |
| Contracted Research | UCB, Stoke Therapeutics, Eisai | |
| Data and Safety Monitoring Board (DSMB) | Jazz Pharmaceuticals, Epygenix Therapeutics |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sarah Milano, RN, has nothing to disclose.
- Nicole Love-Grove, DO, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Daniela DaSilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, dietary, physical, etc). Please contact Med Learning Group prior to the live event at [email protected]
RELEASED DATE: November 27, 2024
EXPIRATION DATE: November 27, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Kelly G. Knupp, MD, MSCS, FAES (CHAIR)
Professor of Pediatrics and Neurology
University of Colorado, Anschutz Medical Campus
Aurora, CO
PROGRAM OVERVIEW
This educational activity is designed to help learners better understand the history of developmental and epileptic encephalopathies (DEEs), utilize genetic evaluation for patients with DEEs, and review best practices for managing the comprehensive burdens of DEEs.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community-based epileptologists, neurologists, and multidisciplinary HCPs including physician assistants, nurse practitioners, LTC nurses, and primary care nurses participating in multi-disciplinary care of patients with epilepsy.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Recognize the need for genetic evaluation of patients with developmental and epileptic encephalopathies (DEEs) as part of diagnostic work-up
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty | Relationship | Manufacturer |
| Kelly G. Knupp, MD | Consultant | Stoke Therapeutics, Encoded Therapeutics, Biocodex, Longboard Pharmaceuticals |
| Contracted Research | UCB, Stoke Therapeutics, Eisai | |
| Data and Safety Monitoring Board (DSMB) | Jazz Pharmaceuticals, Epygenix Therapeutics |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sarah Milano, RN, MSN, has nothing to disclose.
- Nicole Love-Grove, DO, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, dietary, physical, etc). Please contact Med Learning Group prior to the live event at [email protected]
Please listen to the podcast below:
RELEASED DATE: October 31, 2024
EXPIRATION DATE: October 31, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Kelly G. Knupp, MD, MSCS, FAES (CHAIR)
Professor of Pediatrics and Neurology
University of Colorado, Anschutz Medical Campus
Aurora, CO
PROGRAM OVERVIEW
This educational activity is designed to help learners better utilize genetic evaluation for patients with developmental and epileptic encephalopathies (DEEs); understand specific therapies indicated for management of DEEs based on clinical efficacy and safety; and review best practices for transitions of care and involvement of the multidisciplinary health care team.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community-based epileptologists, neurologists, and multidisciplinary HCPs including physician assistants, nurse practitioners, LTC nurses, and primary care nurses participating in multi-disciplinary care of patients with epilepsy.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Support the use of specific therapies indicated for management of DEEs based on clinical efficacy and safety, practical use characteristics, and effects on non-seizure outcomes
- Describe best practices for managing the comprehensive burdens of DEEs through optimized transitions of care as enabled by teams of multidisciplinary health care professionals
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty | Relationship | Manufacturer |
| Kelly G. Knupp, MD | Consultant | Stoke Therapeutics, Encoded Therapeutics, Biocodex, Longboard Pharmaceuticals |
| Contracted Research | UCB, Stoke Therapeutics, Eisai | |
| Data and Safety Monitoring Board (DSMB) | Jazz Pharmaceuticals, Epygenix Therapeutics |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sarah Milano, RN, MSN, has nothing to disclose.
- Nicole Love-Grove, DO, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, dietary, physical, etc). Please contact Med Learning Group prior to the live event at [email protected]
Please listen to the podcast below:
RELEASED DATE: October 31, 2024
EXPIRATION DATE: October 31, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
